Goeckerman therapy (GT) for psoriasis combines the therapeutic effect of crude coal tar (CCT) and ultraviolet radiation (UVR). CCT contains polycyclic aromatic hydrocarbons, some of which can form DNA adducts that may induce mutations and contribute to carcinogenesis. The aim of our work was to evaluate the relationship between concentrations of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts (BPDE-DNA adducts) and rs4646903 (CYP1A1 gene), rs1048943 (CYP1A1), rs1056836 (CYP1B1), rs1051740 (EPHX1), rs2234922 (EPHX1) and rs8175347 (UGT1A1) polymorphic sites, and GSTM1 null polymorphism in 46 patients with chronic stable plaque psoriasis who underwent GT. The level of BPDE-DNA adducts was determined using the OxiSelect BPDE-DNA Adduct ELISA Kit. Polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis (rs4646903, rs1048943, rs1051740, and rs2234922), fragment analysis (rs8175347), real-time PCR (rs1056836), and digital droplet PCR polymorphism (GSTM1) were used. CYP1B1*1/*1 wild-type subjects and CYP1B1*3/*1 heterozygotes for rs1056836 formed significantly higher amounts of BPDE-DNA adducts than CYP1B1*3/*3 homozygotes (p=0.031 and p=0.005, respectively). Regarding rs1051740, individuals with EPHX1*3/*1 heterozygosity revealed fewer adducts than EPHX1*1/*1 wild-type subjects (p=0.026). Our data suggest that CYP1B1/EPHX1 genotyping could help to predict the risk of DNA damage and to optimize doses of coal tar and UVR exposure in psoriatic patients in whom GT was applied.

Clinic of Dermal and Venereal Diseases Charles University Hospital Hradec Kralove 50005 Hradec Kralove Czech Republic

Department of Biochemical Sciences Charles University Prague Faculty of Pharmacy in Hradec Kralove 50005 Hradec Kralove Czech Republic

Institute of Clinical Biochemistry and Diagnostics Charles University Hospital and Faculty of Medicine in Hradec Kralove 50005 Hradec Kralove Czech Republic

Institute of Clinical Immunology and Allergology Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

Institute of Hygiene and Preventive Medicine Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

Institute of Pathological Physiology Charles University Prague Faculty of Medicine in Hradec Kralove 50038 Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc17013851

003      

CZ-PrNML

005      

20170418110346.0

007      

ta

008      

170413s2016 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.toxlet.2016.05.009 $2 doi

035    __

$a (PubMed)27188524

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Beranek, Martin $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital and Faculty of Medicine in Hradec Kralove, 50005 Hradec Kralove, Czech Republic; Department of Biochemical Sciences, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, 50005 Hradec Kralove, Czech Republic.

245    10

$a Genetic polymorphisms in biotransformation enzymes for benzo[a]pyrene and related levels of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in Goeckerman therapy / $c M. Beranek, Z. Fiala, J. Kremlacek, C. Andrys, K. Hamakova, M. Chmelarova, V. Palicka, L. Borska,

520    9_

$a Goeckerman therapy (GT) for psoriasis combines the therapeutic effect of crude coal tar (CCT) and ultraviolet radiation (UVR). CCT contains polycyclic aromatic hydrocarbons, some of which can form DNA adducts that may induce mutations and contribute to carcinogenesis. The aim of our work was to evaluate the relationship between concentrations of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts (BPDE-DNA adducts) and rs4646903 (CYP1A1 gene), rs1048943 (CYP1A1), rs1056836 (CYP1B1), rs1051740 (EPHX1), rs2234922 (EPHX1) and rs8175347 (UGT1A1) polymorphic sites, and GSTM1 null polymorphism in 46 patients with chronic stable plaque psoriasis who underwent GT. The level of BPDE-DNA adducts was determined using the OxiSelect BPDE-DNA Adduct ELISA Kit. Polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis (rs4646903, rs1048943, rs1051740, and rs2234922), fragment analysis (rs8175347), real-time PCR (rs1056836), and digital droplet PCR polymorphism (GSTM1) were used. CYP1B1*1/*1 wild-type subjects and CYP1B1*3/*1 heterozygotes for rs1056836 formed significantly higher amounts of BPDE-DNA adducts than CYP1B1*3/*3 homozygotes (p=0.031 and p=0.005, respectively). Regarding rs1051740, individuals with EPHX1*3/*1 heterozygosity revealed fewer adducts than EPHX1*1/*1 wild-type subjects (p=0.026). Our data suggest that CYP1B1/EPHX1 genotyping could help to predict the risk of DNA damage and to optimize doses of coal tar and UVR exposure in psoriatic patients in whom GT was applied.

650    _2

$a 7,8-dihydro-7,8-dihydroxybenzo(a)pyren 9,10-oxid $x metabolismus $7 D015123

650    _2

$a aplikace kožní $7 D000279

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    _2

$a benzopyren $x aplikace a dávkování $x škodlivé účinky $x metabolismus $7 D001564

650    _2

$a biotransformace $7 D001711

650    _2

$a dehet uhelný $x aplikace a dávkování $x škodlivé účinky $x metabolismus $7 D003033

650    _2

$a cytochrom P450 CYP1B1 $x genetika $x metabolismus $7 D065633

650    _2

$a adukty DNA $x metabolismus $7 D018736

650    _2

$a poškození DNA $7 D004249

650    _2

$a epoxid hydrolasy $x genetika $x metabolismus $7 D004851

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a frekvence genu $7 D005787

650    _2

$a glukuronosyltransferasa $x genetika $x metabolismus $7 D014453

650    _2

$a glutathiontransferasa $x genetika $x metabolismus $7 D005982

650    _2

$a heterozygot $7 D006579

650    _2

$a homozygot $7 D006720

650    _2

$a lidé $7 D006801

650    _2

$a keratolytika $x aplikace a dávkování $x škodlivé účinky $x metabolismus $7 D007641

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a farmakogenetika $7 D010597

650    _2

$a fenotyp $7 D010641

650    12

$a polymorfismus genetický $7 D011110

650    _2

$a psoriáza $x enzymologie $x genetika $x terapie $7 D011565

650    _2

$a kvantitativní polymerázová řetězová reakce $7 D060888

650    _2

$a hodnocení rizik $7 D018570

650    12

$a terapie ultrafialovými paprsky $7 D014467

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

700    1_

$a Fiala, Zdenek $u Institute of Hygiene and Preventive Medicine, Charles University in Prague, Faculty of Medicine in Hradec Kralove, 50038 Hradec Kralove, Czech Republic.

700    1_

$a Kremlacek, Jan $u Institute of Pathological Physiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, 50038 Hradec Kralove, Czech Republic.

700    1_

$a Andrýs, Ctirad $u Institute of Clinical Immunology and Allergology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, 50038 Hradec Kralove, Czech Republic. $7 mzk2008430528

700    1_

$a Hamakova, Kvetoslava $u Clinic of Dermal and Venereal Diseases, Charles University Hospital Hradec Kralove, 50005 Hradec Kralove, Czech Republic.

700    1_

$a Chmelarova, Marcela $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital and Faculty of Medicine in Hradec Kralove, 50005 Hradec Kralove, Czech Republic.

700    1_

$a Palicka, Vladimir $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital and Faculty of Medicine in Hradec Kralove, 50005 Hradec Kralove, Czech Republic.

700    1_

$a Borska, Lenka $u Institute of Pathological Physiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, 50038 Hradec Kralove, Czech Republic. Electronic address: borka@lfhk.cuni.cz.

773    0_

$w MED00004537 $t Toxicology letters $x 1879-3169 $g Roč. 255, č. - (2016), s. 47-51

856    41

$u https://pubmed.ncbi.nlm.nih.gov/27188524 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170413 $b ABA008

991    __

$a 20170418110654 $b ABA008

999    __

$a ok $b bmc $g 1200316 $s 974629

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 255 $c - $d 47-51 $e 20160514 $i 1879-3169 $m Toxicology letters $n Toxicol Lett $x MED00004537

LZP    __

$a Pubmed-20170413